Ousseny Zerbo , PhD

ousseny.x.zerbo@kp.org

Ousseny Zerbo, PhD, is a Research Scientist in the Vaccine Study Center at Kaiser Permanente Northern California Division of Research. His research interest is in maternal vaccination during pregnancy and early childhood health outcomes, vaccine uptake, safety and effectiveness. He is the principal investigator on two NIH-funded projects to investigate the effectiveness of influenza vaccination, COVID-19 vaccination during pregnancy, and infant risk of influenza and COVID-19. He also studies risk factors associated with autism spectrum disorders.

Prior to joining the Vaccine Study Center, he completed post-doctoral training in the Autism Research Program at the Division of Research. He received his PhD in epidemiology from the University of California Davis and his bachelor’s degree in biological science and teaching credential from the University of Ouagadougou, Burkina Faso, West Africa.

Current Positions

Research Scientist II

Section Affiliations

Infectious Diseases

Primary Research Interests

Vaccine safety and effectiveness
Autism spectrum disorder

Related Websites

Kaiser Permanente Vaccine Study Center

Studies

COVID-19 Vaccine Effectiveness in Pregnant Women and their Infants

The overall goals are to: Determine COVID-19 vaccine effectiveness in pregnant women for preventing laboratory-confirmed COVID-19 and hospitalization for COVID-19 using real-world clinical data; Determine effectiveness of maternal COVID-19 vaccination during pregnancy for infants 0-12 months for outcomes of laboratory-confirmed COVID-19, and hospitalization for COVID-19, and determine whether effectiveness varies by trimester of vaccination; Estimate COVID-19 vaccination rates among pregnant women and identify sociodemographic, geographic clusters and other factors associated with being unvaccinated.

Investigator: Zerbo, Ousseny

Funder: National Institute of Allergy and Infectious Diseases

Analysis to evaluate the effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhea

The goal of this study is to use electronic medical records from 2016 to 2020 to evaluate the protective effect of MenB-4C vaccine against gonococcal infections among 16- to 23-year-old persons.

Investigator: Zerbo, Ousseny

Funder: Centers for Disease Control and Prevention

Effect of Maternal Influenza Vaccination during Pregnancy on Risk of Infant Influenza

This project has three major aims: 1) to examine whether influenza vaccination during pregnancy prevents influenza and other respiratory infections in infants aged 0 to 12 months, with a sub-aim to examine the effect of vaccine timing during pregnancy on these outcomes; 2) to evaluate the effect of maternal influenza vaccination during pregnancy on the effectiveness of influenza vaccine administered to infants; and 3) to examine whether influenza non-vaccination during pregnancy clusters geographically, and determine if those clusters are associated with influenza and influenza-like illnesses during pregnancy.

Investigator: Zerbo, Ousseny

Funder: National Institute of Allergy and Infectious Diseases

Publications

Influenza Vaccination Among Pregnant People Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic

Authors: Irving, Stephanie A;Kharbanda, Elyse;Klein, Nicola P;Naleway, Allison L;et al.

Obstet Gynecol. 2023 Sep 01;142(3):636-639. Epub 2023-08-03.

Ousseny Zerbo , PhD

Current Positions

Section Affiliations

Primary Research Interests

Related Websites

Studies

COVID-19 Vaccine Effectiveness in Pregnant Women and their Infants

Analysis to evaluate the effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhea

Effect of Maternal Influenza Vaccination during Pregnancy on Risk of Infant Influenza

Publications

Influenza Vaccination Among Pregnant People Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic

Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 States, June 2021-March 2023

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021

Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years – VISION Network, United States, July 2022-June 2023

Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink

Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination

Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents

Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 – VISION Network, August 2021 – March 2022

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults – VISION Network, Nine States, September-November 2022

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods

Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life

Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults – VISION Network, Nine States, September-November 2022

Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance – VISION Network, 10 States, December 2021-August 2022

Maternal SARS-CoV-2 Vaccination and Infant Protection Against SARS-CoV-2 During the First 6 Months of Life

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination

Safety of COVID-19 Vaccination in US Children Ages 5-11 Years

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated – VISION Network, 10 States, December 2021-June 2022

Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness

Safety of Live-Attenuated Vaccines in Children Exposed to Biologic Response Modifiers in Utero

Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic

Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years – VISION Network, 10 States, April 2021-January 2022

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance – VISION Network, 10 States, August 2021-January 2022

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance – VISION Network, 10 States, August 2021-January 2022

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021

Associations of COVID-19-Related Health, Healthcare and Economic Factors With Prenatal Depression and Anxiety

Contributions of COVID-19 Pandemic-Related Stressors to Racial and Ethnic Disparities in Mental Health During Pregnancy

Population-based assessment of risks for severe COVID-19 disease outcomes

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity – Nine States, January-September 2021

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults – Nine States, January-September 2021

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics – Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021

COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy – Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021

Genetic associations with a fever after measles-containing vaccines

COVID-19 prevalence, symptoms, and sociodemographic disparities in infection among insured pregnant women in Northern California

Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination

Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps﻿-containing vaccines over time

Individual and Neighborhood Factors Associated with Failure to Vaccinate against Influenza during Pregnancy

Risk for Subdeltoid Bursitis After Influenza Vaccination: A Population-Based Cohort Study

Parental Risk Factors for Fever in their Children 7-10 Days After the First Dose of Measles-Containing Vaccines

Order of Live and Inactivated Vaccines and Risk of Non-vaccine-targeted Infections in US Children 11-23 Months of Age

Trivalent inactivated influenza vaccine (IIV3) during pregnancy and six-month infant development

Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season

Infection and Fever in Pregnancy and Autism Spectrum Disorders: Findings from the Study to Explore Early Development

An Exploratory Examination of Neonatal Cytokines and Chemokines as Predictors of Autism Risk: The Early Markers for Autism Study

Acellular Pertussis Vaccine Effectiveness Over Time

Health Care Service Utilization and Cost Among Adults with Autism Spectrum Disorders in a U.S. Integrated Health Care System

Factors Affecting Vaccination in Children and Their Siblings After Autism Spectrum Disorder Diagnosis-Reply

Vaccination Patterns in Children After Autism Spectrum Disorder Diagnosis and in Their Younger Siblings

Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Non-Vaccine-Targeted Infections From 24 Through 47 Months of Age

Use of acellular pertussis vaccines in the United States: can we do better?

No association between influenza vaccination during pregnancy and adverse birth outcomes

Polychlorinated Biphenyl and Organochlorine Pesticide Concentrations in Maternal Mid-Pregnancy Serum Samples: Association with Autism Spectrum Disorder and Intellectual Disability

Autism with intellectual disability is associated with increased levels of maternal cytokines and chemokines during gestation

Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder

Kaiser Permanente Northern California pregnancy database: Description and proof of concept study

Maternal mid-pregnancy C-reactive protein and risk of autism spectrum disorders: the early markers for autism study

Maternal Infection During Pregnancy and Autism Spectrum Disorders

A Study of Physician Knowledge and Experience with Autism in Adults in a Large Integrated Healthcare System

The health status of adults on the autism spectrum

Immune mediated conditions in autism spectrum disorders

Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: the Early Markers for Autism (EMA) study: a case-control study

Is maternal influenza or fever during pregnancy associated with autism or developmental delays? Results from the CHARGE (CHildhood Autism Risks from Genetics and Environment) study

A genome-wide survey of transgenerational genetic effects in autism

​Month of conception and risk of autism

Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps-containing vaccines over time

Month of conception and risk of autism